The possible therapeutic effect of rebamipide and stem cell derivative microvesicles on experimentally provoked colitis in rats: Histological and immuno hisochemical study.

Abstract

Background Ulcerative colitis (UC) is a chronic inflammatory disorder. Clinically, there are periods of pain in abdomen and bloody diarrhea. The used medication induce clinical diminution, but with many difficulties. Aim of the study Evaluation the beneficial outcomes of rebamipide and microvesicles come from mesenchymal stem cells on treatment of induced colitis. Material and methods Fifty adult male albino rats were divided into 5 groups. Group I was the control group. Group II rats received intra-colonic instillation of 1 ml/rat/day of 5% acetic acid (5% v/v) for 3 sequential days. Group III Rats were received a suspension of (1 % rebamipide and 1.5% carboxy-methyl cellulose), intra-colonic in a dose 1 mL/kg/day after provocation of colitis for 14 days. Group IV rats were given out a single dose of 15 μg of microvesicles dissolved in 0.5 ml of phosphate buffered solution (PBS) delivered intravenous in caudal vein after provocation of colitis. Group V rats were given microvesicles and Rebamipide as Group ПI and Group IV after provocation of colitis. The colon sections were managed and examined using histological and immunohistochemical study. Results Group II showed patchy ulceration with loss of surface epithlium and underlying connective tissue. There is infiltration of mononuclear cells and congested blood vessels in lamina propria and sub mucosa. Group III showed near-normal mucosa with surface columnar cell and goblet cells in some areas with discontinuity in certain areas. Group IV showed almost intact mucosa. Group V showed intact mucosa with surface absorptive cells and goblet cells close to control group. Conclusion: Each of rebamipide and microvesicle improved the prompted ulcerative colitis, but their combination was more effective.

Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges

“…BMSCs have been used by several researchers in the treatment of experimental colitis using various animal models, including mice, rats, and Guinea pigs (Table 4). In these animals, some researchers have used trinitrobenzene sulfonic acid (TNBS) to induce colitis [37,[65][66][67][68], while several studies reported the use of dextran sulfate sodium (DSS) to induce colitis models [47,48,[68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83] and many authors applied acetic acid to induce colitis [1,3,4] (Table 4). The first BMSCs transplantation was conducted in 2006 in a TNBS-induced colitis mice model, revealing the important role of cell therapy in the repair of injured intestinal mucosa, as well as the downregulation of immune function of T cells [65].…”

“…The differentiation of BMSCs into colonic interstitial lineage cells could produce TGF-β1 and VEGF that could further participate in the healing of colitis lesions [69]. BMSCs in a DSS-induced colitis rat model were demonstrated to differentiate into several cells, to dampen the inflammation and to repair ulcerations and the distorted crypt architecture, and reduce the loss of surface columnar epithelium [70]. BMSC microvesicles, together with rebamipide in the DSS-induced colitis rat model, resulted in an improvement in the prompted colonic lesions [71].…”